In Q2 of fiscal 2027, the quarter ended Sep 26, 2026, Haemonetics Corporation reported revenue of $357.8 million, up 9.3% from the same quarter a year earlier. Net income was $46.3 million, a profit margin of 12.9%. Operating income came to $75.1 million, an operating margin of 21.0%. Diluted earnings per share were $1.00.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 26, 2026
|
Q2 FY2027
Sep 26, 2026
|
Q1 FY2027
Jun 27, 2026
|
Q4 FY2026
Mar 28, 2026
|
Q3 FY2026
Dec 27, 2025
|
Q2 FY2026
Sep 27, 2025
|
Q1 FY2026
Jun 28, 2025
|
Q4 FY2025
Mar 29, 2025
|
Q3 FY2025
Dec 28, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,382
+4.1%
|
358
+9.3%
|
339
+5.6%
|
346
+4.8%
|
339
-2.7%
|
327
-5.3%
|
321
-4.4%
|
331
-3.7%
|
349
+3.7%
|
| Cost of revenue |
558
+0.7%
|
137
+3.2%
|
137
+5.8%
|
148
+7.7%
|
137
-11.9%
|
133
-16.1%
|
129
-19.9%
|
138
-17.8%
|
155
-2.1%
|
| Gross profit |
824
+6.6%
|
221
+13.4%
|
203
+5.5%
|
198
+2.7%
|
202
+4.6%
|
195
+3.9%
|
192
+9.9%
|
193
+9.7%
|
194
+8.8%
|
| Research and development |
62
-5.2%
|
17
+14.5%
|
16
-0.4%
|
14
-21.1%
|
14
-10.4%
|
15
+5.2%
|
16
+12.5%
|
18
+15.4%
|
16
+19.3%
|
| Selling, general and administrative |
467
+7.7%
|
118
+16.5%
|
119
+7.4%
|
121
+5.0%
|
109
+2.5%
|
102
-5.0%
|
111
+2.3%
|
115
+5.4%
|
106
-4.7%
|
| Restructuring and impairment |
4
-37.8%
|
-0
-211.3%
|
2
+81.5%
|
0
-80.1%
|
1
-58.8%
|
0
-95.7%
|
1
-72.6%
|
1
-83.7%
|
4
-55.9%
|
| Operating income |
177
-27.1%
|
75
+28.4%
|
57
+6.7%
|
-23
-132.3%
|
67
+14.2%
|
58
+13.1%
|
54
+35.5%
|
71
+138.2%
|
59
+28.4%
|
| Other non-operating income (expense) |
-35
-36.4%
|
-12
-70.1%
|
-10
-13.6%
|
-5
-798.7%
|
-7
+18.6%
|
-7
-3.0%
|
-9
-225.1%
|
-1
+90.8%
|
-9
-367.5%
|
| Pretax income |
142
-34.6%
|
63
+22.6%
|
48
+5.3%
|
-28
-140.1%
|
60
+20.1%
|
51
+14.7%
|
45
-3.3%
|
71
+202.1%
|
50
+13.4%
|
| Income tax |
38
-22.1%
|
17
+31.4%
|
15
+30.8%
|
-8
-164.7%
|
15
+22.6%
|
13
+15.9%
|
11
+33.5%
|
13
+318.6%
|
12
-2.9%
|
| Net income |
104
-38.2%
|
46
+19.7%
|
33
-3.0%
|
-20
-134.7%
|
45
+19.3%
|
39
+14.3%
|
34
-11.3%
|
58
+184.7%
|
37
+20.0%
|
| Basic EPS |
2.26
-34.4%
|
1.02
+25.9%
|
0.73
+2.8%
|
-0.44
-137.0%
|
0.96
+28.0%
|
0.81
+22.7%
|
0.71
-5.3%
|
1.18
+193.9%
|
0.75
+21.0%
|
| Diluted EPS |
2.24
-34.7%
|
1.00
+23.5%
|
0.72
+2.9%
|
-0.43
-137.0%
|
0.95
+28.4%
|
0.81
+22.7%
|
0.70
-5.4%
|
1.17
+195.8%
|
0.74
+21.3%
|
| Weighted average shares, basic |
46
-5.8%
|
46
-4.4%
|
45
-5.7%
|
46
-6.0%
|
47
-6.9%
|
48
-6.5%
|
48
-5.6%
|
49
-3.1%
|
50
-0.9%
|
| Weighted average shares, diluted |
46
-5.4%
|
46
-2.5%
|
46
-5.5%
|
46
-6.2%
|
47
-7.2%
|
48
-7.0%
|
48
-6.2%
|
49
-3.7%
|
51
-1.6%
|
| Other measures | |||||||||
| Depreciation and amortization |
110
-4.1%
|
28
-1.8%
|
27
-5.7%
|
27
-3.2%
|
27
-5.7%
|
28
-3.3%
|
29
-1.3%
|
28
+2.1%
|
29
+23.3%
|
| EBITDA |
287
-19.7%
|
103
+18.6%
|
85
+2.3%
|
4
-95.7%
|
95
+7.6%
|
87
+7.2%
|
83
+19.9%
|
100
+72.9%
|
88
+26.7%
|
| Margins | |||||||||
| Gross margin |
59.63%
|
61.75%
|
59.76%
|
57.23%
|
59.71%
|
59.50%
|
59.82%
|
58.39%
|
55.53%
|
| Operating margin |
12.80%
|
21.00%
|
16.93%
|
-6.65%
|
19.88%
|
17.87%
|
16.76%
|
21.58%
|
16.94%
|
| Pretax margin |
10.27%
|
17.57%
|
14.02%
|
-8.20%
|
17.69%
|
15.67%
|
14.05%
|
21.40%
|
14.32%
|
| Profit margin |
7.52%
|
12.94%
|
9.73%
|
-5.82%
|
13.20%
|
11.82%
|
10.59%
|
17.54%
|
10.76%
|
| EBITDA margin |
20.73%
|
28.76%
|
24.92%
|
1.24%
|
27.96%
|
26.50%
|
25.71%
|
30.11%
|
25.26%
|
| Effective tax rate |
26.83%
|
26.34%
|
30.61%
|
—
|
25.40%
|
24.57%
|
24.66%
|
18.03%
|
24.89%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HAE (NYSE)
- Fiscal year ends
- April 3
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 313143
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.